According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...

GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...